non-small cell lung cancer

This Week in PNAS

In PNAS this week: effect of PD-L1 expression on immunotherapy response, endogenous retrovirus segregation in European rabbits, and more.

The new approval will allow the use of Qiagen's Therascreen EGFR RGQ PCR Kit as a companion diagnostic for Pfizer's Vizimpro in NSCLC patients.

The approval includes the use of either tumor tissue or plasma and follows previous approvals with Genentech's Tarceva (erlotinib) and AstraZeneca's Tagrisso (osimertinib).

Two new studies have uncovered expression-defined T cell subsets that seem to coincide with better or worse outcomes in breast cancer or non-small cell lung cancer.

New trial data presented at ASCO highlights the utility of checkpoint inhibitors, alone or with chemotherapy, across PD-L1 expression groups.

This data is helping the agency understand how precision oncology drugs and tests are prescribed outside of clinical trials and in the broader cancer community.

The FDA approved its use with tissue or plasma biopsies, giving clinicians a non-invasive option to conduct a test that provides results in a day.

The partners will evaluate the clinical use of the company's TeloView software with DNA sequence analysis in the treatment of lung cancer.

While the company has historically marketed the test's ability to predict patient drug response, it has more recently focused on its prognostic power.

The company said in April that it planned to launch a test this year but has since decided to take more time to better assess the clinical need and market.

Pages

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.